Abstract Code: IUC25664-88
Whole-Organ Radiotherapy in the Era of Poor Anatomical Resolution: Evidence from a Population-Based Bladder
Cancer Registry (Sri Lanka, 2015–2022)
A. Atchuthan

Abstract Code: IUC25665-89
BK Virus Associated Urothelial Carcinoma – A Regional Cohort of Kidney Transplant Recipients
N. Beetge , L. Ribeiro , C. Horsfield , R. Zakri , J. Olsburgh

Abstract Code: IUC25980-89
Impact of Ureteroscopy on Diagnostic Pathways and Radical Nephroureterectomy Outcomes in Upper Tract Urothelial Carcinoma
A. Maleki, L.F.C. Yu, H. Janebdar, J. Armitage

Abstract Code: IUC26509-87
Real-World Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma
J. Zeb

Abstract Code: IUC26569-93
Enfortumab-Vedotin with Pembrolizumab vs platinum-based therapy for advanced urothelial cancer in Oxford.
T. Al Kharusi , S. San Ti , A. Protheroe , M. Tuthill

Abstract Code: IUC26589-95
First-Line or Maintenance Immune Checkpoint Inhibitors in Older Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
D. Incognito, A. D’arienzo, C. Barraco, A. Nicastro, S. Facchini, G. Facchini, D. Incognito

Abstract Code: IUC26600-79
‘STATE-OF-THE-NATION’ STUDY: UNDERSTANDING NHS TREATMENT PATHWAY TO ADVANCE HR NMIBC
PATIENT CARE in the UK (SPAN UK)
J. Aning, J. Catto, R. Martin, K. Chatterton, P. Mariappan, S. Mccormack, S. Gill, B. Szabados

Abstract Code: IUC26652-86
Clinical impact and safety profile of Enfortumab-vedotin: evaluate the efficacy and safety outcomes obtained in patients diagnosed with metastatic urothelial carcinoma undergoing treatment with Enfortumab Vedotin.
J. Gonzalez Bartolome, A. Almanchel Rivadeneyra, J. Luis Fernandez

Abstract Code: IUC26674-90
Impact of delayed radical cystectomy following neoadjuvant chemotherapy on oncological outcomes in Muscle-invasive bladder cancer
J. Bondjeke Nkumindamu, L. Afani, O. Zouiten, M. El Fadli, R. Belbaraka

Abstract Code: IUC26676-92
HER2-low expression and cell proliferation in urinary bladder carcinomas
M. Dumitru, M. Hortopan, M. Mihaila, C.M. Hotnog, L.I. Brasoveanu, M.E. Panait, M.M. Vasilescu

Abstract Code: IUC26683-90
BlAdder Cancer Circulating biomarkers after treatment exposUre for early detection of relapse: The BACCUS study
E. Mills, A. Bertocchi, P. Rescigno, J. Frew, R. Chandler, X. Jiang, L. Hogarth, M. Mukhiya, V. Conteduca, F. Demichelis

Abstract Code: IUC26685-92
Characterizing the Immune Landscape of Non-Muscle-Invasive Bladder Cancer
G. Fornarini, D. Fenoglio, F. Ferrera, L. Camporesi, A. Lagazio, F. Lo Iacono, T. Altosole, N. Piol, M. Cremante, M. Martiriggiano, P. Traverso, C. Terrone, G. Filaci

Abstract Code: IUC26696-94
Enfortumab Vedotin Plus Pembrolizumab Outcomes in Advanced Urothelial Cancer: Real-World Data
S. Peroos, A. Saeed, S. Jenkinson, A. Clifford, M. Prentice, S. Mansukhani

Abstract Code: IUC26698-96
Durvalumab + BCG therapy in BCG-naïve, high-risk NMIBC: efficacy and safety analyses from POTOMAC
S. Hussain , N. Shore, H. Nishiyama, J. Palou Redorta, M. Krawczynski, A. Seyitkuliev, F. Guerrero-Ramos, M. Kato, T. Powles, M. De Santis

Abstract Code: IUC25511-79
Prostate volume changes during longer fractionated and ultra-hypofractionated MR-guided adaptive radiotherapy leveraging the MOMENTUM registry
S. Cooper, H. Akhiat, S. Alexander, F. Alongi, E. Blezer, A. Choudhury, J. Christodouleas, J. Diaz, C. Gani, S. Hafeez, W. Hall, P. Jeene, M. Luzzara, M. Nowee, T. Schytte, H. Verkooijen, D. Vesprini, J. Van Der Voort Van Zyp, P. Westhoff, A.C. Tree

Abstract Code: IUC26557-90
Retrospective Review of a Prostate Brachytherapy Case cohort Conducted in Botswana: Clinical Outcomes and Adverse Events
A. Bunga, B. Molatodi, R. Tapera, P. Vuylsteke

Abstract Code: IUC26597-94
Longitudinal Trends in Androgen Receptor Pathway Inhibitor Prescribing for Metastatic Prostate Cancer in England Between 2013-2025 Using Real-World Data from the NHS England Prior Approval System
J.K.H. Liu, A. Cook, J. Dodkins, E. Mayne, A. Nathan, J. Nossiter, M.A. Parry, S. Sukumar, R. Fernley, J. Hill, G.L. Banna, M.G. Parry, A.C. Tree, N.W. Clarke, J. Van Der Meulen

Abstract Code: IUC26615-85
Are PSMA (Prostate-Specific Membrane Antigen) PET-CT scans in our unit requested according to NHS England Commissioning Criteria on prostate cancer?
D. Ditri, O.S. Aung, M. Ibrahim, S. Madaan

Abstract Code: IUC26648-91
Cost-effectiveness of Intensity-Modulated Radiation Therapy versus Robot-Assisted Radical Prostatectomy in Patients with Prostate Cancer: A Systematic Review
D. Septiani , N.P. Ayuningtyas

Abstract Code: IUC26651-85
AI-assisted Biparametric vs Multiparametric MRI for Clinically Significant Prostate Cancer
A. Tiwari, K. Bhagat, U. Khan, J.K. Tan, D. Sethi, A. Maniam, G.L. Banna, A. Khan, A. Ghose

Abstract Code: IUC26659-93
Transdermal Estradiol as an Alternative to LHRH Agonists in Prostate Cancer Management
D. Khanna, S. Debra, D. Sethi, M. Abdel-Missih

Abstract Code: IUC26661-86
Real-world outcomes in patients with Metastatic Hormone-Sensitive Prostate Cancer treated with androgen deprivation therapy and Apalutamide – A single centre study
K. Marchon, S. Brown, K. Swaminathan, S. Adeyemi, G. Kapur

Abstract Code: IUC26663-88
Real-world ARASENS triplet therapy in high-volume mHSPC: a single-centre cohort
M.P. Juan Gonzalez, C. Martinez Martinez, A.J. Montalban Valverde, P.A. Barranzuela
Decoll, Y. El Farh Boumajdil, E.J. Soria Hernandez, B. Riesco Montes, E. Nogueron Martinez

Abstract Code: IUC26665-90
Global inequalities in prostate cancer incidence and mortality: an ecological analysis
M. Hosseini, Y. Vaez-Gharamaleki, A. Motamedi

Abstract Code: IUC26669-94
The LDR BURST Trial: A Randomised Comparison of Toxicity Outcomes following LDR Brachytherapy vs 5-Fraction SBRT with a Rectal Spacer for Localised Prostate Cancer
W. Hayhurst, S. Uribe-Lewis, J. Uribe, C. Mikropoulos, S. Otter, C. Goh, S. Mehta, A. Michael, S. Langley, C. Perna

Abstract Code: IUC26673-89
Reducing adverse outcomes following local anaesthetic trans-perineal prostate biopsies
S. Moshtael, M. Johnston, G. Crowther, J. Brewin

Abstract Code: IUC26679-95
A pilot study of the implementation of the G8 frailty assessment in oncology clinics for patients with newly diagnosed metastatic hormone sensitive prostate cancer
A. Hague, S. Appleyard, A. Balagopal, N. Samkaoui

Abstract Code: IUC26688-95
S100A9 Identifies Distinct Circulating Myeloid Cell Subsets in Metastatic Prostate Cancer
C. Iglesias, M.F. Guerra, R. Hinojosa Altamirano, M. Beckel, A. Bruke, E. Sandes, M.N. Gandur Quiroga, Y. Langle

Abstract Code: IUC25516-84
Non clear renal cell carcinoma: metastatic patterns and survival from a real‑world cohort
H. Maamoun, M. Al-Essa, I. Pedley, A. Azzabi, S. Grumett, M. Elgendy

Abstract Code: IUC25517-85
Title: First‑line TKI, ipilimumab–nivolumab, and lenvatinib–pembrolizumab in metastatic non–clear cell RCC: real‑world survival across two UK centres
H. Maamoun, M. Al-Essa, I. Pedley, A. Azzabi, S. Grumett, M. Elgendy

Abstract Code: IUC26559-92
Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Evidence
from an Immunotherapy-Inaccessible Cohort
A. Krishnan M P, P. Shenoy, N. Devi R, A. Menon, S. Nawaz

Abstract Code: IUC26562-86
Integrating Transcriptomic Profiles and Clinical Outcomes Across MEET-URO Risk Groups in Metastatic Renal Cell Carcinoma: A Comparative Analysis with the IMDC Framework
G. Neola, N. Salgia, A. Moradi, S.E. Rebuzzi, P. Rescigno, S.K. Pal, G.L. Banna

Abstract Code: IUC26657-91
Sex-based Disparities in Metastatic Renal Cell Carcinoma: Real-World Data from Meet-URO33 Study.
M. Zinelli Ronzoni, M. Maffezzoli, E. Lai, E. Verzoni, C. Lolli, M. Di Napoli, A. Signori, S. Buti, S.E. Rebuzzi, D. Bimbatti

Abstract Code: IUC26658-92
Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations
D. Khanna, T. Dey, E. Blanchard-Cavagis, B. Gonsalves, A. Benedict, M. Job, D. Omoregie, S. Basu, O. Benny, A. Maniam, G.L. Banna, R. Kanesvaran, Y. Urun, K.
Jatwani, M.N. Gandur-Quiroga, M. Anwar, J.K. Tan, S.E. Rebuzzi, R.D. Frazer, A. Ghose

Abstract Code: IUC26671-87
Adjuvant Pembrolizumab in RCC: Real world experience in Northern Ireland 2022-2026
S. Buchanan, G. Clements, C. Forde, A. Clayton

Abstract Code: IUC26672-88
Treatment beyond progression in primary refractory mRCC during 1L systemic therapy (Meet-Uro 33)
D. Aspden, D. Bimbatti, A. Dalla Volta, G. Roviello, R. Iacovelli, G. Bozza, M.G. Vitale, E. Fantinel, A. Guida, F.M. Deppieri, C. Nasso, S. Scagliarini, E. Cocorocchio, B. Maiorano, C. Caserta, A. Cavo, F. Paolieri, F. La Russa, L. Fratino, S.E. Rebuzzi

Abstract Code: IUC26682-89
Efficacy and tolerability of immune checkpoint inhibitors in older versus younger patients with metastatic renal cell carcinoma: a real-world Asian cohort
R. Kanesvaran, H.S. Tan, J.W.K. Chan, W.C. Tan, D.J.M. Ang, J.J.X. Tan, H.X. Tan, A. Roy Chowdhury

Abstract Code: IUC26686-93
Synergistic potential of cabozantinib and radiotherapy in advanced renal cell carcinoma by site of irradiation
F. Di Costanzo, A. Bertocchi, M.L. Esposito, I.S. Parisi, A. Federico, P.A. Zucali, L. Formisano, C. Oing, R. Chandler, P. Rescigno

Abstract Code: IUC26691-89
Real-World Outcomes of Delayed Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Following Systemic Therapy: A Tertiary Centre Experience
M. Hassan, H. Warren, R. Nair, D. Crawley, A. Khan, A. Fernando, T. O Brein, S. Rudman

Abstract Code: IUC26693-91
CHOLESTEROL HOMEOSTASIS AND IMMUNE-INFLAMMATORY PROFILES IN PATIENTS WITH mRCC RECEIVING IMMUNOTHERAPY
P. Tuttobene, M. Maffezzoli, G. Leali, M. Pluchino, E. Favari, G. Mazzaschi, F. Pecci, M. Tiseo, M. Di Maio, S. Buti

Abstract Code: IUC26695-93
Real-world Outcomes of First-line Immune Checkpoint Inhibitor–Tyrosine Kinase Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: A Regional Cancer Centre Experience
R. Gul, E. Fetherston, O. Oghenevwede, O. Shahin, K. Kumar

Abstract Code: IUC26697-95
First Line Tyrosine Kinase Inhibitors (TKIs) in metastatic Renal Cell Cancer (mRCC)- A regional cancer Centre experience.
R. Gul, O. Oghenevwede, E. Fetherston, O. Shahin, K. Kumar

Abstract Code: IUC26700-80
Real world analysis of first line systemic anti-cancer treatment for metastatic Renal cell carcinoma
E. Woods, S. Growcott, A. Gee

Abstract Code: IUC26498-94
Diagnostic Pathway Delay in Penile Squamous Cell Carcinoma: a UK Regional Cohort Study
J.M. Haider

Abstract Code: IUC26510-79
Spondias Mombin Leaf Extract show selective toxicity to testicular cancer cells lines in vitro
E. Proudman, P. Savage

Abstract Code: IUC26664-89
De-escalated management of stage I seminoma: three decades of real-world outcomes
M.P. Juan Gonzalez, C. Martinez Martinez, A.J. Montalban Valverde, P.A. Barranzuela Decoll, Y. El Farh Boumajdil, E.J. Soria Hernandez, J.A. Mendez Garcia, E. Adrover Cebrian, A. Fernandez Aramburo

Abstract Code: IUC26668-93
Clinicopathological Features, Treatment Patterns and Outcomes in Small Cell Carcinoma of the Prostate and Urinary Bladder: A Retrospective Study from an Indian Tertiary Care Centre
A. Sharma, M. Chettri, M. Pallati, R. Bisht, P. Pandey, R. Jain, S. Panaiyadiyan, P. Singh, B. Nayak, A. Singhal, A. Sharma, A. Narwal, S. Kaushal, R. Kumar Sahoo, A. Batra

Abstract Code: IUC26681-88
Carboplatin AUC 10 in Good-Prognosis Metastatic Seminoma: A Portuguese Real-World Experience
A. Figueiredo, J. Pedro Barata, S. Magno, F. Vaz

Abstract Code: IUC26687-94
Clinical and Pathologic Outcomes of Resection of Thoracic Residual Masses in Germ Cell Tumors
S. Jubran, E. Erbetta, V. Verzeletti, A. Di Marco, C. Pittarello, D. Bimbatti, F. Pierantoni, M. Maruzzo, A. Dell’amore, U. Basso

Abstract Code: IUC25592-88
Exploring the Use of AI-Enhanced Virtual Reality in Teaching and Evaluating Communication Skills in Urology: A Pilot Study
M. Saad

Abstract Code: IUC26660-85
Severe immune checkpoint inhibitor toxicity drives additional costs
M. Khanjra, M. Emmerich, J. Larkin, Z. Tippu, S. Turajlic